Automate Your Wheel Strategy on MDGL
With Tiblio's Option Bot, you can configure your own wheel strategy including MDGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDGL
- Rev/Share 23.2155
- Book/Share 31.3405
- PB 14.0879
- Debt/Equity 0.1781
- CurrentRatio 5.1061
- ROIC -0.3779
- MktCap 9841039280.0
- FreeCF/Share -13.8869
- PFCF -31.9113
- PE -34.7814
- Debt/Assets 0.1221
- DivYield 0
- ROE -0.3838
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MDGL | H.C. Wainwright | -- | Buy | -- | $500 | Sept. 4, 2025 |
| Upgrade | MDGL | B. Riley Securities | Neutral | Buy | $236 | $422 | Feb. 28, 2025 |
| Reiterated | MDGL | H.C. Wainwright | -- | Buy | $400 | $405 | Feb. 27, 2025 |
News
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Presentation Unknown Analyst Good morning, everyone. Very excited to be kicking off the Morgan Stanley Healthcare Conference with the Madrigal team this morning.
Read More
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Read More
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
Published: August 15, 2025 by: Seeking Alpha
Sentiment: Positive
Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmaceuticals still reported a net loss of $42.3M, though profitability may be near. Approval of Rezdiffra in the EU could come in August 2025, with a launch by MDGL in Germany in H2 '25 possible.
Read More
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
Read More
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.
Read More
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.
Read More
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Read More
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Read More
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.
Read More
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Read More
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage.
Read More
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Read More
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights.
Read More
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Read More
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
Read More
About Madrigal Pharmaceuticals, Inc. (MDGL)
- IPO Date 2007-02-06
- Website https://www.madrigalpharma.com
- Industry Biotechnology
- CEO William J. Sibold
- Employees 528